P2Y12 receptor antagonist

This page covers all P2Y12 receptor antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting P2Y12, P2Y12 receptor.

Targets

P2Y12 · P2Y12 receptor

Marketed (8)

• low-dose ticagrelor · First Affiliated Hospital of Harbin Medical University · Cardiovascular
  Low-dose ticagrelor inhibits the P2Y12 adenosine diphosphate receptor on platelets to reduce platelet aggregation and thrombotic events.
• prasugrel or ticagrelor · University of Florida · Cardiovascular
  Both prasugrel and ticagrelor are P2Y12 platelet adenosine diphosphate receptor antagonists that inhibit platelet aggregation and reduce thrombotic events.
• half-dose ticagrelor · First Affiliated Hospital of Harbin Medical University · Cardiovascular
  Half-dose ticagrelor inhibits the P2Y12 adenosine diphosphate receptor on platelets to reduce platelet aggregation and thrombotic events.
• standard-dose ticagrelor · First Affiliated Hospital of Harbin Medical University · Cardiovascular
  Ticagrelor is a P2Y12 receptor antagonist that irreversibly blocks platelet activation and aggregation, reducing thrombotic events.
• P2Y12 antagonist monotherapy · Samsung Medical Center · Cardiovascular
  P2Y12 antagonists block the P2Y12 adenosine diphosphate receptor on platelet surfaces, preventing platelet aggregation and thrombus formation.
• Ticagrelor or Prasugrel · St. Antonius Hospital · Cardiovascular
  Both ticagrelor and prasugrel are P2Y12 receptor antagonists that inhibit platelet aggregation by blocking ADP-mediated platelet activation.
• Ticagrelor first · Ping-Yen Liu · Cardiovascular
  Ticagrelor is a direct-acting P2Y12 receptor antagonist that inhibits platelet aggregation by blocking adenosine diphosphate (ADP) signaling.
• P2Y12 Receptor Antagonist · Fu Wai Hospital, Beijing, China · Cardiovascular
  Blocks the P2Y12 adenosine diphosphate receptor on platelets to inhibit platelet aggregation and reduce thrombotic events.

Phase 3 pipeline (1)

• conventional-dose ticagrelor · First Affiliated Hospital of Harbin Medical University · Cardiovascular
  Ticagrelor is a platelet aggregation inhibitor that works by blocking the P2Y12 receptor.